Allergan INC (Formerly Actavis INC )
Pharmaceutical manufacturer specializing in generic, brand and biosimilar products.
Based in DC
🤖
AI Overview
With $520K in lobbying spend across 10 quarterly filings, Allergan INC (Formerly Actavis INC ) is an active lobbying client. Their lobbying covers 5 issue areas. Active from 2018 to 2020.
$520K
Total Spend
3
Years Active
1
Firms Hired
2
Lobbyists Deployed
5
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $200K |
| 2020 | $120K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Pharmacy, Copyright/Patent, Taxation, Health Issues, Budget/Appropriations
- •Monitor issues concerning bioequivalence standards for pharmaceuticals.
- •Advocate for Inter Partes Review (IPR) reform concerning pharmaceuticals.
- •Monitor technical corrections to H.R. 1, the Tax Cuts and Jobs Act.
- •Advocate for voluntary best practices related to pharmaceutical pricing. Engage with policymakers on Medicare Part D prescription drug benefit as related to HR 1892, the Bipartisan Budget Act of 2018.
- •Advocate for FDA oversight of compounded medicines as related to the HR 1625, the Consolidated Appropriations Act of 2018.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
The 22,000% ROI
When lobbying spending yields outsized returns.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
Similar Clients
National Association of Benefits and Insurance Professionals
$8.6M total spend
F Hoffmann-la Roche LTD and its Affiliates
$4.0M total spend
Biotechnology Industry Organization
$2.8M total spend
The Campaign for Sustainable Rx Pricing
$2.6M total spend
National Organization for Rare Disorders INC (Nord)
$2.1M total spend
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.